PFA Pension Forsikringsaktieselskab Acquires New Holdings in Elevance Health, Inc. $ELV

Key Points

• PFA Pension acquired a new stake of 187,317 shares of Elevance Health (about 0.08% ownership), valued at roughly $65.34 million in Q4 per its 13F filing.
• Elevance reported a quarterly EPS beat—$12.58 vs. $10.74 consensus—and revenue of $49.49 billion, and has set FY2026 EPS guidance around 19.85.
• The company announced a quarterly dividend of $1.72 (annualized $6.88) implying a ~1.8% yield, with an ex-dividend date of June 10 and payment on June 25.

PFA Pension Forsikringsaktieselskab acquired a new stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 187,317 shares of the company's stock, valued at approximately $65,336,000. PFA Pension Forsikringsaktieselskab owned approximately 0.08% of Elevance Health as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sei Investments Co. grew its holdings in Elevance Health by 7.7% during the second quarter. Sei Investments Co. now owns 163,668 shares of the company's stock worth $63,666,000 after acquiring an additional 11,745 shares during the period. Glenview Trust co grew its holdings in Elevance Health by 41.5% during the second quarter. Glenview Trust co now owns 1,619 shares of the company's stock worth $630,000 after acquiring an additional 475 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Elevance Health by 6.9% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company's stock worth $25,650,000 after acquiring an additional 4,272 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Elevance Health by 5.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company's stock worth $16,478,000 after acquiring an additional 2,012 shares during the period. Finally, Quantinno Capital Management LP grew its holdings in Elevance Health by 111.8% during the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company's stock worth $17,080,000 after acquiring an additional 23,180 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Down 1.0%

Shares of Elevance Health stock opened at $372.78 on Friday. The stock has a 50-day moving average price of $310.69 and a 200 day moving average price of $331.77. The company has a market cap of $80.95 billion, a P/E ratio of 15.86, a P/E/G ratio of 2.12 and a beta of 0.66. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $424.24.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business's revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the prior year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health's dividend payout ratio is currently 29.26%.

Analyst Ratings Changes

A number of research analysts recently issued reports on ELV shares. Guggenheim lifted their target price on Elevance Health from $396.00 to $399.00 and gave the stock a "buy" rating in a report on Friday, April 24th. JPMorgan Chase & Co. lifted their target price on Elevance Health from $397.00 to $411.00 and gave the stock an "overweight" rating in a report on Tuesday, April 28th. Wells Fargo & Company lowered their target price on Elevance Health from $424.00 to $391.00 and set an "overweight" rating on the stock in a report on Friday, January 30th. Jefferies Financial Group decreased their price target on Elevance Health from $395.00 to $391.00 and set a "buy" rating for the company in a research report on Monday, April 20th. Finally, Mizuho decreased their price target on Elevance Health from $413.00 to $350.00 and set an "outperform" rating for the company in a research report on Wednesday, March 11th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $384.58.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.